301277.SHE Henan Newland Pharmaceutical Co. Ltd. A
- Market cap
- CNY 3.49B
- P/E
- 32.9x
- P/B
- 2.26x
- ROE
- 7.9%
- Dividend yield
- 3.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 301277.SHE undervalued?
Graham number301277.SHE trades 82.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Henan Newland Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Henan Newland Pharmaceutical Co. Ltd. A yet.
Henan Newland Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vild…
Full company profileHenan Newland Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Henan Newland Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 433M | 514M | 627M | 651M | 726M | 672M | 794M |
| Gross Profit | 197M | 206M | 223M | 260M | 295M | 235M | 242M |
| Operating Income | 147M | 150M | 149M | 161M | 191M | 133M | 151M |
| EBITDA | - | - | 174M | 212M | 235M | 190M | 138M |
| Net Income | 118M | 115M | 132M | 159M | 174M | 121M | 122M |
| EPS | 0.56 | 0.39 | 0.34 | 0.41 | 0.44 | 0.31 | 0.31 |
| Balance Sheet | |||||||
| Total Assets | 522M | 668M | 1.53B | 1.61B | 1.81B | 1.78B | 1.75B |
| Total Liabilities | 209M | 262M | 175M | 160M | 271M | 228M | 222M |
| Shareholders' Equity | 313M | 403M | 1.36B | 1.45B | 1.54B | 1.55B | 1.53B |
| Cash & Short-term Investments | 36.3M | 34.2M | 51.1M | 270M | 282M | 169M | 158M |
| Cash Flow | |||||||
| Operating Cash Flow | 47.9M | 49.1M | 82.8M | 259M | 127M | 117M | - |
| Capital Expenditure | 17.0M | 25.4M | 74.3M | 96.5M | 111M | 101M | 36.7M |
| Free Cash Flow | 30.9M | 23.7M | 8.50M | 163M | 16.0M | 15.6M | -22.7M |
| Ratios | |||||||
| ROE | 37.8% | 28.6% | 9.8% | 11.0% | 11.3% | 7.8% | 7.9% |
| ROA | 22.7% | 17.2% | 8.6% | 9.9% | 9.6% | 6.8% | 6.9% |
| Net Profit Margin | 27.3% | 22.4% | 21.1% | 24.4% | 23.9% | 18.0% | 15.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Henan Newland Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 3.21%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 92.4%
- Ex-dividend date
- Apr 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 112M | 0.29 | 92.4% |
| 2024 | CNY 80.0M | 0.20 | 46.1% |
| 2023 | CNY 66.7M | 0.17 | 41.9% |
| 2022 | CNY 6.77M | 0.02 | 5.1% |
| 2021 | CNY 36.7M | 0.12 | 31.9% |
| 2020 | CNY 54.5M | 0.26 | 46.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Apr 16, 2025.
Who owns Henan Newland Pharmaceutical Co. Ltd. A
- Insiders 75.42%
- Institutions 0.43%
- Public & others 24.15%
- Shares outstanding 392M
- Free float 99.6M
Henan Newland Pharmaceutical Co. Ltd. A company profile
- Company name
- Henan Newland Pharmaceutical Co. Ltd. A
- Ticker
- 301277.SHE
- ISIN
- CNE1000065K2
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 981
- Fiscal year end
- December
- Address
- East side of the southern section of Weiwu Road, Changge, China, 461500
- Phone
- 86 37 4610 5083
- Website
- newlandpharma.com
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge, China.
Henan Newland Pharmaceutical Co. Ltd. A management
5- Mr. Luwei ZhangGM & Director · born 1971
- Mr. Qingkui WangFinancial Director & Accounting Supervisor · born 1979
- Mr. Chao LiuDeputy GM & Employee Representative Director · born 1986
- Ms. Yushan XieSecretary of the Board of Directors · born 1992
- Mr. Liying WangDeputy General Manager · born 1975